LitCovid-sample-Enju  

PMC:7253482 / 0-345 JSONTXT 15 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T0 0-15 NNS denotes Vulnerabilities
T1 16-18 IN denotes in
T2 19-30 NN denotes coronavirus
T3 31-37 NN denotes glycan
T4 38-45 NNS denotes shields
T5 46-53 IN denotes despite
T6 54-63 JJ denotes extensive
T7 64-77 NN denotes glycosylation
T8 79-87 NN denotes Abstract
T9 88-94 JJ denotes Severe
T10 95-100 JJ denotes acute
T11 101-112 JJ denotes respiratory
T12 113-121 NN denotes syndrome
T13 122-123 -LRB- denotes (
T14 123-127 NN denotes SARS
T15 127-128 -RRB- denotes )
T16 129-132 CC denotes and
T17 133-139 NNP denotes Middle
T18 140-144 NNP denotes East
T19 145-156 JJ denotes respiratory
T20 157-165 NN denotes syndrome
T21 166-167 -LRB- denotes (
T22 167-171 NNS denotes MERS
T23 171-172 -RRB- denotes )
T24 173-186 NNS denotes coronaviruses
T25 187-188 -LRB- denotes (
T26 188-192 NNS denotes CoVs
T27 192-193 -RRB- denotes )
T28 194-197 VBP denotes are
T29 198-206 JJ denotes zoonotic
T30 207-216 NNS denotes pathogens
T31 217-221 IN denotes with
T32 222-226 JJ denotes high
T33 227-235 NN denotes fatality
T34 236-241 NNS denotes rates
T35 242-245 CC denotes and
T36 246-254 JJ denotes pandemic
T37 255-264 NN denotes potential
T38 266-273 NN denotes Vaccine
T39 274-285 NN denotes development
T40 286-293 VBZ denotes focuses
T41 294-296 IN denotes on
T42 297-300 DT denotes the
T43 301-310 JJ denotes principal
T44 311-317 NN denotes target
T45 318-320 IN denotes of
T46 321-324 DT denotes the
T47 325-337 VBG denotes neutralizing
T48 338-345 JJ denotes humoral
R0 T0 T1 arg1Of Vulnerabilities,in
R1 T4 T1 arg2Of shields,in
R10 T12 T13 arg1Of syndrome,(
R11 T14 T13 arg2Of SARS,(
R12 T15 T13 arg3Of ),(
R13 T12 T16 arg1Of syndrome,and
R14 T20 T16 arg2Of syndrome,and
R15 T18 T17 arg1Of East,Middle
R16 T20 T18 arg1Of syndrome,East
R17 T20 T19 arg1Of syndrome,respiratory
R18 T20 T21 arg1Of syndrome,(
R19 T22 T21 arg2Of MERS,(
R2 T4 T2 arg1Of shields,coronavirus
R20 T23 T21 arg3Of ),(
R21 T28 T24 arg1Of are,coronaviruses
R22 T24 T25 arg1Of coronaviruses,(
R23 T26 T25 arg2Of CoVs,(
R24 T27 T25 arg3Of ),(
R25 T16 T28 arg1Of and,are
R26 T30 T28 arg2Of pathogens,are
R27 T30 T29 arg1Of pathogens,zoonotic
R28 T30 T31 arg1Of pathogens,with
R29 T35 T31 arg2Of and,with
R3 T4 T3 arg1Of shields,glycan
R30 T34 T32 arg1Of rates,high
R31 T34 T33 arg1Of rates,fatality
R32 T34 T35 arg1Of rates,and
R33 T37 T35 arg2Of potential,and
R34 T37 T36 arg1Of potential,pandemic
R35 T39 T38 arg1Of development,Vaccine
R36 T39 T40 arg1Of development,focuses
R37 T40 T41 arg1Of focuses,on
R38 T44 T41 arg2Of target,on
R39 T44 T42 arg1Of target,the
R4 T0 T5 arg1Of Vulnerabilities,despite
R40 T44 T43 arg1Of target,principal
R41 T44 T45 arg1Of target,of
R5 T7 T5 arg2Of glycosylation,despite
R6 T7 T6 arg1Of glycosylation,extensive
R7 T12 T9 arg1Of syndrome,Severe
R8 T12 T10 arg1Of syndrome,acute
R9 T12 T11 arg1Of syndrome,respiratory